Magnetoencephalography Market Size & Share 2026-2035

Magnetoencephalography Market Size

The magnetoencephalography (MEG) market was valued at USD 290.7 million in 2025, is expected to reach USD 316.0 million in 2026, is projected to grow at a 7.8% CAGR (2026–2035), and is expected to reach USD 614.0 million by 2035.

The magnetoencephalography (MEG) market is evolving from a narrowly concentrated capital-equipment category toward a broader clinical and research platform market. Demand is supported by epilepsy surgery programs, advanced functional mapping workflows, recurring software and service needs, and the gradual commercialization of OPM systems that can reduce dependence on cryogenic infrastructure.

Magnetoencephalography Market Trends, Growth Drivers & GMI Forecast Outlook

The market outlook reflects durable demand from specialized clinical neuroscience centers and research institutions, alongside a technology transition that is widening the feasible installation base. Growth remains conditioned by reimbursement, capital planning, magnetic-shielding requirements, and the ability of OPM platforms to move from validated research settings into scaled clinical deployment.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Epilepsy creates the most established clinical demand pathway because MEG can localize interictal activity when scalp EEG is non-localizing or structural imaging does not provide a clear surgical target. The wider neurological disease burden is also substantial: more than 3 billion people lived with neurological conditions in 2021, and these conditions were the leading global source of disability-adjusted life years ^{[2]World Health Organization. "Over 1 in 3 people affected by neurological conditions — the leading cause of illness and disability worldwide." who.int}. Within specialized epilepsy programs, that burden translates into demand for a diagnostic modality that can improve confidence in surgical candidacy and cortical localization.

Public neuroscience funding supports MEG procurement not only as a research investment, but also as an institutional capability that links neuroscience discovery, clinician training, and clinical service development. The NIH BRAIN Initiative provides a continuing policy signal for neurotechnology infrastructure ^{[3]National Institutes of Health. "Budget." nih.gov}. Comparable support from European research programs and national research councils can strengthen the case for systems that serve both experimental neuroscience and clinical neurophysiology workflows, while software upgrades extend the value of an installed system after the initial equipment purchase.

OPM-MEG is reshaping the technology proposition by moving sensing closer to the scalp and removing the continuous liquid-helium dependency associated with conventional systems. A peer-reviewed validation study found comparable task-evoked oscillatory patterns and field topographies between whole-scalp OPM-MEG and SQUID-MEG in a 100-participant sample ^{[7]Multiple authors. "Performance of optically pumped magnetometer magnetoencephalography: validation in large samples and multiple tasks." iopscience.iop.org}. The practical significance is greatest for pediatric, motion-tolerant, and wearable use cases, where conventional fixed helmet geometry can constrain acquisition quality and patient access.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

The disease burden and the commercial opportunity are not distributed evenly. Clinical MEG remains concentrated in university hospitals, comprehensive epilepsy centers, and advanced neuroscience institutions in markets with established capital infrastructure and specialist staffing. WHO identifies epilepsy as a major chronic brain disease globally ^{[1]World Health Organization. "Epilepsy." who.int}, but the availability of high-acuity neuroimaging and epilepsy surgery pathways remains uneven. As a result, near-term growth is more likely to arise from system replacement, program expansion, and selected first-time installations than from broad-based global diffusion.

Academic demand is also exposed to the timing of public funding cycles. NIH budget information underscores that neurotechnology appropriations can fluctuate ^{[3]National Institutes of Health. "Budget." nih.gov}, creating uncertainty around capital projects that depend on grant alignment and institutional co-investment. At the same time, reimbursement for clinical MEG remains most established in epilepsy-related pathways, limiting the near-term monetization of emerging applications in neurodegenerative, psychiatric, and neurodevelopmental care.

Site preparation remains a material obstacle. Magnetically shielded rooms require specialized engineering, multi-layer shielding, structural assessment, and commissioning before clinical operation. The resulting deployment timeline, spatial footprint, and capital commitment favor tertiary hospitals and academic medical centers. OPM platforms can reduce some of these barriers, but their broader effect depends on commercial maturity, clinical workflows, and regulatory adoption.

Magnetoencephalography Market Segment Analysis

By Technology

The magnetoencephalography (MEG) market remains anchored in cryogenic clinical infrastructure, while OPM systems are creating a distinct growth path centered on portability, patient comfort, and infrastructure simplification.

Cryogenic SQUID MEG Systems

Cryogenic SQUID MEG systems accounted for 88.0% of the market in 2025 and are projected to generate USD 485.1 million by 2035. Their installed-base advantage rests on clinical familiarity, established validation in epilepsy programs, compatibility with existing neurophysiology workflows, and recurring service and upgrade requirements. Even as OPM alternatives advance, centers with magnetically shielded facilities and trained technical teams retain a strong economic incentive to preserve and modernize SQUID-based capability.

OPM MEG systems generated USD 34.9 million in 2025 and are expected to grow at a 13.9% CAGR (2026–2035). The segment is positioned around flexible sensor placement, near-scalp signal capture, and operation without cryogenic cooling. Its commercial relevance is especially pronounced for pediatric neurology, movement-tolerant acquisition, and institutions that have historically found conventional MEG infrastructure too burdensome.

By Component

MEG Systems/Devices

MEG Systems/Devices generated USD 192.9 million in 2025 and are projected to reach USD 388.8 million by 2035. Hardware remains the primary transaction value pool because a complete installation combines sensor arrays, acquisition electronics, system integration, and, in applicable contracts, shielding infrastructure. Demand is shaped by replacement cycles at established sites and selected new installations at tertiary neuroscience centers.

Software

Software held a 15.0% share in 2025 and is expected to grow at a 9.0% CAGR (2026–2035). Source localization, acquisition management, connectivity analysis, reporting, and AI-assisted interpretation are increasing the strategic importance of software in the installed base. The category can support recurring manufacturer relationships while helping clinical sites manage specialist interpretation capacity and integrate MEG findings into multidisciplinary care decisions.

Services

Services generated USD 54.2 million in 2025 and are projected to account for a 19.9% revenue share by 2035. Installation, maintenance, training, remote monitoring, cryogenic support, and preventive servicing are integral to uptime in systems used for high-consequence clinical decisions. This recurring revenue layer also reinforces switching costs, particularly where hospitals rely on vendor-specific technical expertise.

By Application

Clinical

Clinical applications generated USD 210.7 million in 2025 and are projected to reach USD 459.5 million by 2035. The segment is supported by the role of MEG in presurgical epilepsy assessment and functional cortex mapping, where temporal resolution and source-localization capability can complement structural imaging and electrophysiology. Broader clinical adoption will depend on the progression of evidence and reimbursement beyond the most established indications.

Epilepsy Diagnosis & Pre-Surgical Mapping generated USD 84.3 million in 2025 and is projected to reach USD 189.5 million by 2035. It remains the central clinical demand engine because MEG can support localization in complex cases where conventional tests are inconclusive. Expansion of comprehensive epilepsy surgery programs and pediatric surgical pathways should sustain the application's strategic importance.

Brain Tumor Localization & Functional Cortex Mapping

Brain Tumor Localization & Functional Cortex Mapping represented an 11.6% market share in 2025 and is projected to generate USD 73.5 million by 2035. Demand is linked to preoperative assessment of eloquent cortex when surgeons must balance tumor resection with preservation of language, motor, and sensory function. The application is well suited to academic neurosurgery programs that can combine MEG outputs with other functional mapping approaches.

Dementia & Neurodegenerative Disorders

Dementia & Neurodegenerative Disorders generated USD 29.4 million in 2025 and are expected to account for a 9.3% share by 2035. Current demand is shaped primarily by biomarker research, including work on oscillatory changes and functional-network disruption. Commercial expansion is likely to depend on whether research findings become reproducible, clinically actionable, and reimbursable diagnostic pathways.

Autism Spectrum Disorder

Autism Spectrum Disorder accounted for a 5.8% share in 2025 and is expected to grow at a 9.4% CAGR (2026–2035). MEG research in auditory processing, sensory gating, and neural synchrony aligns closely with the advantages of wearable and pediatric-oriented OPM configurations. The segment's progression is therefore tied not only to clinical evidence, but also to the availability of patient-friendly acquisition systems.

Schizophrenia

Schizophrenia generated USD 10.5 million in 2025 and is projected to reach USD 27.9 million by 2035. Interest in gamma oscillations and mismatch-negativity abnormalities gives MEG a differentiated role in research and translational psychiatry. Wider commercial adoption will require evidence that these signals can improve diagnostic stratification, treatment selection, or longitudinal assessment in real clinical settings.

Multiple Sclerosis, Stroke, Traumatic Brain Injury, and Other Clinical Applications

Multiple Sclerosis accounted for a 3.6% share in 2025, Stroke is projected to grow at a 5.8% CAGR (2026–2035), and Traumatic Brain Injury represented a 2.9% share in 2025. These applications reflect different stages of clinical development, from cognitive-network research to neurorehabilitation assessment and mild-injury signal detection. Their common constraint is the need to convert promising research utility into standardized clinical pathways with clear payer and provider value.

Research

Research generated USD 80.0 million in 2025 and is projected to reach USD 154.5 million by 2035. Cognitive neuroscience, sensory research, language and memory mapping, and biomarker development continue to rely on MEG's combination of temporal resolution and source-localization capability. Procurement remains sensitive to grant cycles, but the modality's role in investigating neural dynamics preserves its importance in major academic environments.

By End User

Hospitals & Clinics

Hospitals & Clinics generated USD 133.7 million in 2025 and are projected to reach USD 275.4 million by 2035. Demand is concentrated in tertiary institutions with epilepsy surgery programs, functional mapping needs, dedicated neuroimaging capacity, and sufficient clinical throughput to justify specialized infrastructure. Service contracts and software upgrades further extend revenue beyond initial system placement.

Imaging Centers

Imaging Centers held a 19.0% share in 2025 and are projected to grow at an 8.3% CAGR (2026–2035). MEG-capable imaging centers generally operate through close clinical affiliations rather than as conventional general-radiology facilities. Their opportunity depends on referral density, access to specialist interpretation, and the ability to position MEG within an advanced functional-neuroimaging service line.

Academic & Research Institutes

Academic & Research Institutes generated USD 101.8 million in 2025 and are projected to account for a 35.1% share by 2035. These institutions remain foundational customers because they combine basic neuroscience research, clinical training, and translational program development. Their purchasing decisions are complex, often requiring alignment across grant funding, laboratory priorities, hospital partnerships, and long-term facility plans.

Magnetoencephalography Market Regional Analysis

North America Magnetoencephalography (MEG) Market Analysis

The magnetoencephalography (MEG) market in North America generated USD 116.3 million in 2025 and is projected to reach USD 221.0 million by 2035. The region benefits from comprehensive epilepsy centers, deep academic neuroscience networks, established regulatory processes, and a large base of tertiary hospitals capable of supporting specialized imaging infrastructure. Replacement demand, software monetization, and clinical program expansion should remain central to regional growth.

United States

The United States generated USD 101.2 million in 2025 and is projected to reach USD 190.5 million by 2035. Its market is sustained by academic medical centers, neuroscience funding, and established epilepsy surgery pathways. MEGIN's MEG Maps platform received FDA 510(k) clearance for U.S. market entry, reinforcing the regulatory route for advanced MEG system offerings ^{[4]MEGIN Oy. "MEGIN's MEG Maps™ to transform the field of neuroscience, a field that is still limited by the performance of conventional neuroimaging modalities to date." megin.com}.

Canada

Canada accounted for a 5.2% share in 2025 and is expected to grow at a 7.3% CAGR (2026–2035). Installations are concentrated in research-intensive universities and specialized neurology centers. Investment in system renewal and comprehensive epilepsy evaluation capacity should support steady adoption, though procurement remains tied to institutional and provincial funding priorities.

Europe Magnetoencephalography (MEG) Market Analysis

Europe represented a 33.0% share in 2025 and is projected to generate USD 184.2 million by 2035. Its market combines mature clinical installations with strong university-based neuroscience ecosystems. Longstanding expertise in MEG methodology, public research funding, and the presence of established manufacturers create a favorable environment for service renewals, system upgrades, and carefully targeted new-site development.

Germany

Germany generated USD 21.1 million in 2025 and is projected to reach USD 41.6 million by 2035. University hospitals, neurodegenerative research programs, and established clinical-research collaboration provide a durable demand base. MEG systems serve both patient-facing functional mapping requirements and broader neuroscience investigation, supporting a balanced mix of equipment, software, and service needs.

United Kingdom

The United Kingdom held a 6.6% share in 2025 and is expected to grow at a 7.1% CAGR (2026–2035). Its installed base is supported by leading academic institutions and neuroimaging centers. Continued research funding and the ability to integrate MEG into collaborative clinical-research programs remain important determinants of procurement activity.

France

France generated USD 14.4 million in 2025 and is expected to hold a 4.5% share by 2035. Demand is centered on university hospitals and neuroscience programs with established interest in epilepsy and functional mapping. The market is characterized by mature-site refresh activity, complemented by selective investments in institutions building advanced neurosurgical capabilities.

Finland

Finland accounted for a 4.0% share in 2025 and is projected to generate USD 22.1 million by 2035. The country's market benefits from its strong MEG research heritage and close institutional links between neuroscience centers and domestic system expertise. This ecosystem supports continued use of MEG for both methodological innovation and high-acuity clinical applications.

Netherlands

The Netherlands generated USD 7.7 million in 2025 and is projected to reach USD 14.7 million by 2035. University hospitals and academic neuroscience centers provide the principal demand base. Clinical epilepsy evaluation and cognitive neuroscience research reinforce each other, helping sustain utilization across both patient-care and research workflows.

Asia Pacific Magnetoencephalography (MEG) Market Analysis

The magnetoencephalography (MEG) market in Asia Pacific generated USD 61.0 million in 2025 and is projected to grow at a 10.5% CAGR (2026–2035). The region's expansion is supported by Japan's established clinical environment, China's neuroscience investment, South Korea's technology-development capabilities, and growing advanced-neuroimaging activity across other regional markets. New system placement potential is comparatively stronger than in more mature regions.

Japan

Japan generated USD 19.5 million in 2025 and is projected to reach USD 49.1 million by 2035. National reimbursement support and a longstanding clinical-research installed base provide a stable foundation for demand. Local supplier relationships and hospital-affiliated research programs should continue to support equipment renewal and clinical utilization.

China

China held a 5.9% share in 2025 and is projected to grow at an 11.1% CAGR (2026–2035). Expanding neuroscience infrastructure, domestic supplier development, and a growing neurosurgery base create a meaningful long-term opportunity. The market's strategic importance stems from the combination of institutional demand growth and increasing local technical capability.

South Korea

South Korea generated USD 9.8 million in 2025 and is expected to account for a 4.0% share by 2035. The country combines demand from university research programs with participation in advanced MEG sensor development. This dual role supports its position as both an end-user market and a technology-development node within the regional ecosystem.

Australia

Australia accounted for a 2.1% share in 2025 and is projected to generate USD 15.0 million by 2035. Major university hospitals and neuroscience institutions underpin demand across clinical epilepsy workups and fundamental research. Local industry presence and regional collaboration can support the country's role in broader Asia Pacific commercialization.

Latin America Magnetoencephalography (MEG) Market Analysis

Latin America represented a 3.5% share in 2025 and is projected to grow at a 9.2% CAGR (2026–2035). Demand is concentrated in flagship neurology centers and academic institutions in the region's largest healthcare markets. Capital constraints, limited reimbursement, and shortages of specialized technical personnel continue to restrict broader diffusion.

Brazil

Brazil generated USD 5.7 million in 2025 and is expected to grow at a 9.5% CAGR (2026–2035). Demand is primarily linked to federal university hospitals, specialty neuroscience institutions, and developing epilepsy surgery programs. Adoption will depend on the ability of major centers to align advanced imaging investments with clinical referral networks and research partnerships.

Mexico

Mexico accounted for a 0.9% share in 2025 and is projected to generate USD 6.1 million by 2035. Market activity is concentrated in specialty neurology centers and high-tier private hospitals. Advanced diagnostic capacity and academic collaboration can support selective growth, although access remains limited beyond major metropolitan healthcare systems.

Middle East & Africa Magnetoencephalography (MEG) Market Analysis

The magnetoencephalography (MEG) market in Middle East & Africa generated USD 7.3 million in 2025 and is expected to account for a 3.0% share by 2035. Growth is concentrated in high-investment Gulf healthcare systems, while much of Sub-Saharan Africa remains outside the commercially addressable market because of infrastructure, staffing, and reimbursement constraints.

Saudi Arabia

Saudi Arabia generated USD 2.6 million in 2025 and is projected to grow at a 10.1% CAGR (2026–2035). Healthcare transformation programs and investment in tertiary neurological care can support adoption at advanced hospitals and academic medical centers. The market's potential is closely tied to the pace at which specialized epilepsy and neurosurgery pathways are developed.

United Arab Emirates

The United Arab Emirates accounted for a 0.8% share in 2025 and is projected to generate USD 5.5 million by 2035. Investment in high-acuity neurology and neurosurgery services supports the positioning of MEG as a differentiated diagnostic capability. Medical-tourism ambitions and hospital development priorities may create opportunities for carefully targeted installations.

South Africa

South Africa generated USD 1.2 million in 2025 and is expected to account for a 0.5% share by 2035. Installations remain limited to a small number of academic medical centers and research institutions. Public-sector resource constraints and the absence of broad reimbursement for specialized neuroimaging continue to limit wider clinical adoption.

Magnetoencephalography Market Share & Competitive Landscape

The magnetoencephalography (MEG) market share structure is highly concentrated, with the top five companies accounting for approximately 93% of global revenue in 2025. Competitive positioning is shaped by engineering expertise, clinical validation, regulatory capability, magnetic-shielding integration, installed-base service relationships, and proprietary software ecosystems. These barriers favor suppliers with the capacity to support customers across installation, maintenance, training, and long-term workflow optimization.

MEGIN Oy

MEGIN Oy held approximately 42% of global market revenue in 2025. Its competitive position reflects an established portfolio of cryogenic MEG systems, strong relationships with neuroscience institutions, and broad commercial reach across key clinical and research markets. The company's strategic emphasis on integrated imaging and analytic workflows positions it to defend installed-base relationships while pursuing applications beyond traditional research settings.

CTF MEG Neuro Innovations Inc.

CTF MEG Neuro Innovations Inc. held a 22% share in 2025. The company's high-channel-count SQUID systems, integrated shielding solutions, helium-recovery capabilities, and refurbishment offerings provide a comprehensive proposition for institutions seeking to manage lifecycle cost and infrastructure complexity. Its installed base in academic and clinical settings supports recurring service and upgrade opportunities.

Yokogawa Electric Corporation

Yokogawa Electric Corporation held a 16% share in 2025. Its market position is particularly strong in Japan, where established institutional relationships and the clinical MEG environment support a durable domestic base. The company's broader precision-instrumentation capabilities may also support participation in regional expansion as advanced neuroimaging capacity develops across Asia Pacific.

Ricoh Company Ltd.

Ricoh Company Ltd. is developing a position in OPM-MEG through wearable-system innovation and precision optical expertise. Its opportunity is tied to the transition toward ambient-temperature sensor platforms, where manufacturing capability and sensor-integration know-how could become increasingly important. The company's strategic relevance lies in its potential to participate in a market shift rather than in conventional installed-base competition alone.

Compumedics Neuroscan

Compumedics Neuroscan has a growing presence in Asia Pacific through its MEG system portfolio and technology partnerships. Its focus on adult and pediatric sensing architecture addresses a practical limitation in conventional MEG deployment, while its regional relationships may support commercial development in academic and clinical neuroscience markets outside the traditional North American and European centers.

Recent Industry Developments

MEGIN announced a partnership with MYndspan on February 27, 2025, to deploy MEGIN-powered brain scanning within a consumer-accessible brain health center in London ^{[5]MEGIN Oy. "MYndspan and MEGIN Partner to Make MEG Brain Scans More Accessible." megin.com}. The partnership broadens the commercial conversation around MEG beyond conventional hospital referral and academic procurement models, although the durability of consumer-facing demand will depend on clinical positioning, workflow scalability, and the value proposition for users.

Compumedics announced on May 14, 2025, that its Orion LifeSpan MEG system had achieved dual adult- and pediatric-optimized recordings at Tianjin Normal University ^{[6]Compumedics Limited. "Compumedics Achieves World-First Adult and Child Optimised Recordings from a Single MEG System." compumedics.com.au}. The milestone highlights the commercial relevance of flexible sensor configurations for pediatric neuroscience and could strengthen the case for systems designed to serve a broader patient-age range without requiring separate platforms.